SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (14555)2/10/1998 11:13:00 PM
From: Henry Niman  Respond to of 32384
 
Bob, The earnings beyond 2000 already rise quite dramatically. I think that retinoid sales are expected to grow to $100-$200 million if indications remain small (CTCL, APL, KS), but move to 1/2 Billion if one or two larger indications is thrown in (and I think that we will hear about one or two larger indications very soon).



To: Machaon who wrote (14555)2/10/1998 11:16:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
LGND's approach really is an alternative to chemo, and it has many pluses. Side effects are milder and drug is taken in pill form (and for KS it's the one a day kind). That's probably what is most remarkable about tonight's results. It's not a special case (like APL), and treatment involves popping one pill a day.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News